CD8 and CD4 T cell-mediated polymyositis complicating the HTLV-1 associated myelopathy. Quantitative evaluation of corticosteroid treatment.
BACKGROUND
Inflammatory myopathy is a treatable cause of worsening in the spectrum of neurological conditions that may develop during the course of HTLV-1 infection.


METHODS
To investigate the cause of subacute worsening in the strength of a 46-y-old black male with HTLV-1 associated myelopathy we performed electrodiagnostic examination and a muscle biopsy which was studied with histochemistry, immunocytochemistry and electron microscopy. Serial measurements of isometric muscle strength were performed during the course of corticosteroid treatment.


RESULTS
The muscle biopsy showed evidence of denervation atrophy and prominent inflammatory changes with autoaggressive features. Lymphocyte typing showed a predominance of CD8+ T cells. The patient had sustained, marked improvement in strength, especially of the upper extremities, with oral, high single-dose, alternate-day prednisone therapy.


CONCLUSIONS
A muscle biopsy should be considered in all patients with HTLV-1 associated weakness, especially when electromyography indicates possible coexisting primary muscle involvement and/or serum creatine kinase levels are elevated. HTLV-1-associated polymyositis can be successfully treated with corticosteroids.
Neuromuscular Unit, University of Wisconsin Medical School, Madison 53792, USA.
A J
AJ
Waclawik
R
R
Fadic
B P
BP
Lotz
B R
BR
Beinlich
P J
PJ
Lewandoski
M
M
Sanjak
B R
BR
Brooks
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D015704:CD4 Antigens / Q000276:immunology*; D016827:CD8 Antigens / Q000276:immunology*; D003402:Creatine Kinase / Q000097:blood; D005455:Fluorescent Antibody Technique; D015490:HTLV-I Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000737:chemistry; D015493:Paraparesis, Tropical Spastic / Q000150:complications* / Q000188:drug therapy; D017285:Polymyositis / Q000150:complications* / Q000188:drug therapy; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D015704:CD4 Antigens; D016827:CD8 Antigens; D003402:Creatine Kinase; D011241:Prednisone